Paliperidone Palmitate News and Research

RSS
Janssen announces CHMP positive opinion for use of paliperidone palmitate 3-monthly injection for schizophrenia treatment

Janssen announces CHMP positive opinion for use of paliperidone palmitate 3-monthly injection for schizophrenia treatment

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen announces submission of NDA for three-month paliperidone palmitate

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Little efficacy difference between old and new antipsychotics

Little efficacy difference between old and new antipsychotics

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

EDT receives European approval for XEPLION injection to treat schizophrenia

EDT receives European approval for XEPLION injection to treat schizophrenia

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA